Jan den Hartigh
- Name
- Dr. J. den Hartigh
- Telephone
- +31 71 526 2755
- j.den.hartigh@umail.leidenuniv.nl
- Faculteit Geneeskunde
- Divisie 4
- Klinische Farmacie en Toxicologie
- Toxicologie
- Nibberinga, P.H.; Goblyos, A.; Adriaans, A.E.; Cordfunke, R.A.; Ravensbergen, B.; Rietveld, M.H.; Zwart, S.; Commandeur, S.; Leeuwen, R. van; Haisma, E.M.; Schimmel, K.J.M.; Hartigh, J. den; Drijfhout, J.W. & Ghalbzouri, A. el (2019), Eradication of meticillin-resistant Staphylococcus aureus from human skin by the novel LL-37-derived peptide P10 in four pharmaceutical ointments, International Journal of Antimicrobial Agents 54(5): 610-618.
- Vanbrabant, T.J.F.; Dijkmans, A.C.; Hartigh, J. den; Touw, D.J. & Arend, S.M. (2018), Rifampin levels in daily practice: the accuracy of a single measurement, Netherlands Journal of Medicine 76(5): 235-242.
- Melchers, M.J.; Mil, A.C. van; Lagarde, C.; Hartigh, J. den & Mouton, J.W. (2017), Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model, Antimicrobial Agents and Chemotherapy 61(9).
- Haisma, E.M.; Goblyos, A.; Ravensbergen, B.; Adriaans, A.E.; Cordfunke, R.A.; Schrumpf, J.; Limpens, R.W.A.L.; Schimmel, K.J.M.; Hartigh, J. den; Hiemstra, P.S.; Drijfhout, J.W.; Ghalbzouri, A. el & Nibbering, P.H. (2016), Antimicrobial Peptide P60.4Ac-Containing Creams and Gel for Eradication of Methicillin-Resistant Staphylococcus aureus from Cultured Skin and Airway Epithelial Surfaces, Antimicrobial Agents and Chemotherapy 60(7): 4063-4072.
- Wit, D. de; Schneider, T.C.; Moes, D.J.A.R.; Roozen, C.F.M.; Hartigh, J. den; Gelderblom, H.; Guchelaar, H.J.; Hoeven, J.J. van der; Links, T.P.; Kapiteijn, E. & Erp, N.P. van (2016), Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer, Cancer Chemotherapy and Pharmacology 78(1): 63-71.
- Moes, D.J.A.R.; Swen, J.J.; Bent, S.A.S. van der; Straaten, T. van der; Inderson, A.; Olofsen, E.; Verspaget, H.W.; Guchelaar, H.J.; Hartigh, J. den & Hoek, B. van (2016), Response: Limited sampling strategies for once daily tacrolimus exposure monitoring, European Journal of Clinical Pharmacology 72(6): 775-776.
- Moes, D.J.A.R.; Bent, S.A.S. van der; Swen, J.J.; Straaten, T. van der; Inderson, A.; Olofsen, E.; Verspaget, H.W.; Guchelaar, H.J.; Hartigh, J. den & Hoek, B. van (2016), Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients, European Journal of Clinical Pharmacology 72(2): 163-174.
- Wit, D. de; Erp, N.P. van; Hartigh, J. den; Wolterbeek, R.; Hollander-van Deursen, M. den; Labots, M.; Guchelaar, H.J.; Verheul, H.M. & Gelderblom, H. (2015), Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib: A Pharmacokinetic Feasibility Study, Therapeutic Drug Monitoring 37(3): 331-338.
- Wit, D. de; Guchelaar, H.J.; Hartigh, J. den; Gelderblom, H. & Erp, N.P. van (2015), Individualized dosing of tyrosine kinase inhibitors: are we there yet?, Drug Discovery Today 20(1): 18-36.
- Wit, D. de; Hartigh, J. den; Gelderblom, H.; Qian, Y.W.; Hollander, M. den; Verheul, H.; Guchelaar, H.J. & Erp, N.P. van (2015), Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Pazopanib, Journal of Clinical Pharmacology 55(12): 1344-1350.
- Kerkhofs, T.M.A.; Derijks, L.J.J.; Ettaieb, H.; Hartigh, J. den; Neef, K.; Gelderblom, H.; Guchelaar, H.J. & Haak, H.R. (2015), Development of a Pharmacokinetic Model of Mitotane: Toward Personalized Dosing in Adrenocortical Carcinoma, Therapeutic Drug Monitoring 37(1): 58-65.
- Dezentje, V.O.; Opdam, F.L.; Gelderblom, H.; Hartigh, J. den; Straaten, T. van der; Vree, R.; Maartense, E.; Smorenburg, C.H.; Putter, H.; Dieudonne, A.S.; Neven, P.; Velde, C.J.H. van de; Nortier, J.W.R. & Guchelaar, H.J. (2015), CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects, Breast Cancer Research and Treatment 153(3): 583-590.
- Welzen, M.E.B.; Dezentje, V.O.; Schaik, R.H.N. van; Colbers, A.P.H.; Guchelaar, H.J.; Erp, N.P. van; Hartigh, J. den; Burger, D.M. & Laarhoven, H.W.M. van (2015), The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity, Therapeutic Drug Monitoring 37(4): 501-507.
- Rongen, A. van; Kervezee, L.; , J.E.B. m; Meir, H. van; Hartigh, J. den; Guchelaar, H.J.; Meijer, J.H.; Burggraaf, J. & Oosterhout, F. van (2015), Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers, CPT: Pharmacometrics and Systems Pharmacology 4(8): 454-464.
- Iersel, L.B.J. van; Leede, E.M. de; Vahrmeijer, A.L.; Tijl, F.G.J.; Hartigh, J. den; Kuppen, P.J.K.; Hartgrink, H.H.; Gelderblom, H.; Nortier, J.W.R.; Tollenaar, R.A.E.M. & Velde, C.J.H. van de (2014), Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study, EJSO - European Journal of Surgical Oncology 40(11): 1557-1563.
- Brink, M.H. ten; Bredius, R.G.M.; Zwaveling, J.; Ackaert, O.; Hartigh, J. den; Smiers, F.J.; Guchelaar, H.J. & Lankester, A. (2014), Treosulfan-Based Conditioning in Pediatric Hematopoietic Stem Cell Transplantation: A Prospective Study on Pharmacokinetics and Early Clinical Outcomes, Blood 124(21).
- Brink, M. ten; Bredius, R.; Zwaveling, J.; Smiers, F.; Hartigh, J. den; Guchelaar, H.J.; Lankester, A. & Pediat Dis Inborn Errors (2014), THE PHARMACOKINETIC PROFILE OF TREOSULFAN IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Bone Marrow Transplantation 49: S364-S365.
- Langers, P.; Press, R.R.; Inderson, A.; Cremers, S.C.L.M.; Hartigh, J. den; Baranski, A.G. & Hoek, B. van (2014), Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation, Therapeutic Drug Monitoring 36(2): 141-147.
- Moes, D.J.A.R.; Bent, S.A.S. van der; Swen, J.J.; Straaten, T.; Verspaget, H.W.; Guchelaar, H.J.; Hartigh, J. den & Hoek, B. van (2014), Population Pharmacokinetics and Pharmacogenetics of Once Daily Tacrolimus Formulation in Liver Transplant Patients., Liver Transplantation 20: S106-S107.
- Brink, M. ten; Ackaert, O.; Zwaveling, J.; Bredius, R.G.; Smiers, F.J.; Hartigh, J. den; Lankester, A.C. & Guchelaar, H. (2014), Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation, Therapeutic Drug Monitoring 36(4): 465-472.
- Kerkhofs, T.M.A.; Derijks, L.J.J.; Ettaieb, M.H.T.; Eekhoff, E.M.W.; Neef, C.; Gelderblom, H.; Hartigh, J. den; Guchelaar, H.J. & Haak, H.R. (2014), Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring, European Journal of Endocrinology 171(6): 677-683.
- Wit, D. de; Gelderblom, H.; Sparreboom, A.; Hartigh, J. den; Hollander, M. den; Konig-Quartel, J.M.C.; Hessing, T.; Guchelaar, H.J. & Erp, N.P. van (2014), Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer, Cancer Chemotherapy and Pharmacology 73(1): 87-96.
- Erp, N.P. van; Wit, D. de; Guchelaar, H.J.; Gelderblom, H.; Hessing, T.J. & Hartigh, J. den (2013), A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry, Journal of Chromatography B 937: 33-43.
- Moes, D.J.A.R.; Swen, J.J.; Hartigh, J. den; Straaten, T. van der; Heide, J.J.H. van der; Bemelman, F.; Fijter, J.W. de & Guchelaar, H.J. (2013), Evaluating the Effect of CYP3A4 and CYP3A5 Polymorphisms on Cyclosporine, Everolimus and Tacrolimus Pharmacokinetics in Renal Transplantation Patients, Therapeutic Drug Monitoring 35(5): 672-672.
- Opdam, F.L.; Dezentje, V.O.; Hartigh, J. den; Modak, A.S.; Vree, R.; Batman, E.; Smorenburg, C.H.; Nortier, J.W.R.; Gelderblom, H. & Guchelaar, H.J. (2013), The use of the C-13-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels, Cancer Chemotherapy and Pharmacology 71(3): 593-601.
- Goblyos, A.; Schimmel, K.J.M.; Valentijn, A.R.P.M.; Fathers, L.M.; Cordfunke, R.A.; Chan, H.L.; Oostendorp, J.; Nibbering, P.H.; Drijfhout, J.W.; Hiemstra, P.S. & Hartigh, J. den (2013), Development of a Nose Cream Containing the Synthetic Antimicrobial Peptide P60.4Ac for Eradication of Methicillin-Resistant Staphylococcus aureus Carriage, Journal of Pharmaceutical Sciences 102(10): 3539-3544.
- Siiskonen, S.J.; Koomen, E.R.; Visser, L.E.; Herings, R.M.C.; Guchelaar, H.J.; Stricker, B.H.C. & Nijsten, T.E.C. (2013), Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma, European Journal of Clinical Pharmacology 69(7): 1437-1444.
- Erp, N.P. van; Wit, D. de; Sparreboom, A.; Hartigh, J. den; Hollander, M. den; Konig-Quartel, J.M.C.; Hessing, T.; Guchelaar, H.J. & Gelderblom, H. (2013), CYP3A4 phenotyping with midazolam to predict sunitinib exposure., Journal of Clinical Oncology 31(15).
- Daleboudt, G.M.N.; Reinders, M.E.J.; Hartigh, J. den; Huizinga, T.W.J.; Rabelink, A.J.; Fijter, J.W. de & Berger, S.P. (2013), Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil, Lupus 22(2): 171-179.
- Opdam, F.; Dezentje, V.O.; Hartigh, J. den; Guchelaar, H.J.; Hessing, T.; Straaten, T. van der; Vree, R.; Batman, E.; Maartense, E.; Smorenburg, C.H.; Zeillemaker, A.; Brakenhoff, J.A.C.; , M. los; Kuijer, P.; Putter, H.; Dieudonne, A.S.; Maven, P.; Velde, C.J.H. van de; Nortier, J.W.R. & Gelderblom, H. (2013), Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers., Journal of Clinical Oncology 31(15).
- Mourer, J.S.; Hartigh, J. den; Zwet, E.W. van; Mallat, M.J.K.; Dubbeld, J. & Fijter, J.W. de (2012), Randomized Trial Comparing Late Concentration-Controlled Calcineurin Inhibitor or Mycophenolate Mofetil Withdrawal, Transplantation 93(9): 887-894.
- Dijkmans, A.C.; Hartigh, J. den; Dissel, J.T. van & Burggraaf, J. (2012), A Simplified Oral Flucloxacillin Absorption Test for Patients Requiring Long-Term Treatment, Therapeutic Drug Monitoring 34(3): 356-358.
- Swartjes, M.; Mooren, R.A.G.; Waxman, A.R.; Arout, C.; Wetering, K. van de; Hartigh, J. den; Beijnen, J.H.; Kest, B. & Dahan, A. (2012), Morphine Induces Hyperalgesia without Involvement of mu-Opioid Receptor or Morphine-3-glucuronide, Molecular Medicine 18(9): 1320-1326.
- Hermsen, I.G.; Fassnacht, M.; Terzolo, M.; Houterman, S.; Hartigh, J. den; Leboulleux, S.; Daffara, F.; Berruti, A.; Chadarevian, R.; Schlumberger, M.; Allolio, B.; Haak, H.R. & Baudin, E. (2011), Plasma Concentrations of o,p ' DDD, o,p ' DDA, and o,p ' DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study, Journal of Clinical Endocrinology and Metabolism 96(6): 1844-1851.
- Sparidans, R.W.; Martens, I.; Valkenburg-van Iersel, L.B.J.; Hartigh, J. den; Schelleris, J.H.M. & Beijnen, J.H. (2011), Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma, Journal of Chromatography B 879(21): 1851-1856.
- Erp, N.P. van; Baker, S.D.; Zandvliet, A.S.; Ploeger, B.A.; Hollander, M. den; Chen, Z.Y.; Hartigh, J. den; Konig-Quartel, J.M.C.; Guchelaar, H.J. & Gelderblom, H. (2011), Marginal increase of sunitinib exposure by grapefruit juice, Cancer Chemotherapy and Pharmacology 67(3): 695-703.
- Erp, N.P. van; Guchelaar, H.J.; Ploeger, B.A.; Romijn, J.A.; Hartigh, J. den & Gelderblom, H. (2011), Mitotane has a strong and a durable inducing effect on CYP3A4 activity, European Journal of Endocrinology 164(4): 621-626.
- Fijter, J.W. de; Ewe, S.H.; Hartigh, J. den; Ng, A.C.T.; Delgado, V.; Mallat, M.J.K.; Bax, J.J.; Ringers, J.; Rabelink, T.J. & Mourer, J.S. (2011), Beneficial Effects of Late Concentratiqon-Controlled CNI Withdrawal in Renal Transplant Recipients., American Journal of Transplantation 11: 406-406.
- Hermsen, I.G.C.; Fassnacht, M.; Terzolo, M.; Houterman, S.; Hartigh, J. den; Leboulleux, S.; Daffara, F.; Allolio, B.; Berruti, A.; Chadarevian, R.; Haak, H.R. & Baudin, E. (2010), Plasma Concentration of o,p'DDD (Mitotane), o,p'DDA and o,p'DDE as Predictors of Tumor Response in Adrenocortical Carcinoma: Results of a Retrospective European Network for the Study of Adrenal Tumors (ENS@T) Multicentre Study., Endocrine Reviews 31(3): -.
- Rossum, H.H. van; Press, R.R.; Hartigh, J. den & Fijter, J.W. de (2010), POINT - A Call for Advanced Pharmacokinetic and Pharmacodynamic Monitoring to Guide Calcineurin Inhibitor Dosing in Renal Transplant Recipients, Clinical Chemistry 56(5): 732-735.
- Moes, D.J.A.R.; Press, R.R.; Fijter, J.W. de; Guchelaar, H.J. & Hartigh, J. den (2010), Liquid Chromatography-Tandem Mass Spectrometry Outperforms Fluorescence Polarization Immunoassay in Monitoring Everolimus Therapy in Renal Transplantation, Therapeutic Drug Monitoring 32(4): 413-419.
- Nieuwkoop, C. van; Exter, P.L. den; Elzevier, H.W.; Hartigh, J. den & Dissel, J.T. van (2010), Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation, International Journal of Antimicrobial Agents 36(6): 485-490.
- Press, R.R.; Ploeger, B.A.; Hartigh, J. den; Straaten, T. van der; Pelt, H. van; Danhof, M.; Fijter, H. de & Guchelaar, H.J. (2010), Explaining variability in ciclosporin exposure in adult kidney transplant recipients, European Journal of Clinical Pharmacology 66(6): 579-590.
- Willemze, A.J.; Press, R.R.; Lankester, A.C.; Egeler, R.M.; Hartigh, J. den & Vossen, J.M. (2010), CsA exposure is associated with acute GVHD and relapse in children after SCT, Bone Marrow Transplantation 45(6): 1056-1061.
- Olofsen, E.; Mooren, R.; Dorp, E. van; Aarts, L.; Smith, T.; Hartigh, J. den; Dahan, A. & Sarton, E. (2010), Arterial and Venous Pharmacokinetics of Morphine-6-Glucuronide and Impact of Sample Site on Pharmacodynamic Parameter Estimates, Anesthesia and Analgesia 111(3): 626-632.
- Jolink, H.; Hartigh, J. den; Visser, L.G. & Nieuwkoop, C. van (2010), Pancytopenia due to proguanil toxicity in a returning traveller with fever, European Journal of Clinical Pharmacology 66(8): 811-812.
- Hermsen, I.G.C.; Hartigh, J. den & Haak, H.R. (2010), Mitotane serum level analysis; good agreement between two different assays, Clinical Endocrinology 73(2): 271-272.
- Wirtz P.W., Verschuuren J.J., Dijk J.G. van, Kam M.L. de, Schoemaker R.C., Hasselt J.G.C. van, Titulaer M.J., Tjaden U.R., Hartigh J. den & Gerven J.M.A. van (2009), Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study, Clinical Pharmacology & Therapeutics 86(1): 44-48.
- Burggraaf, K.; Krikken-Hogenberk, L.; Engbers, F.; Wilde, R. de; Hartigh, J. den & Arbous, S. (2009), DEVELOPMENT AND EVALUATION OF A CONTINUOUS INTRAVENOUS INFUSION OF ACETAMINOPHEN IN CARDIAC SURGERY PATIENTS, Basic and Clinical Pharmacology and Toxicology 105: 26-27.
- van der Vorst MMJ, van Heijst AFJ, den Hartigh J & Burggraaf J (2009), Therapeutic drug monitoring for furosemide in neonates on ECMO, British Journal of Clinical Pharmacology 68(5): 792-793.
- van der Vorst M, van Heijst A, den Hartigh J & Burggraaf J (2009), FUROSEMIDE THERAPEUTIC DRUG MONITORING IN NEONATES ON EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO), Basic and Clinical Pharmacology and Toxicology 105: 130-131.
- Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JGC, Titulaer MJ, Tjaden UR, den Hartigh J & van Gerven JMA (2009), Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert-Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study, Clinical Pharmacology and Therapeutics 86(1): 44-48.
- Press RR, van Rossum HH, Ploeger BA, den Hartigh J, van Pelt J, Guchelaar HJ, de Fijter JW & Danhof M (2009), Is Calcineurin Activity Useful as a Biomarker to Optimize Cyclosporine a Therapy in Renal Transplant Recipients?, Therapeutic Drug Monitoring 31(5): 620-620.
- Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW & Guchelaar HJ (2009), Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients, Therapeutic Drug Monitoring 31(2): 187-197.
- Zandvliet ML, Falkenburg JHF, Jedema I, Willemze R, Guchelaar HJ & Meij P (2009), Detailed Analysis of IFNg Response Upon Activation Permits Efficient Isolation of Cytomegalovirus-specific CD8(+) T Cells for Adoptive Immunotherapy, Journal of Immunotherapy 32(5): 513-523.
- Burggraaf, K.; Krikken-Hogenberk, L.; Engbers, F.; Wilde, R. de; Hartigh, J. den & Arbous, S. (2009), DEVELOPMENT AND EVALUATION OF A CONTINUOUS INTRAVENOUS INFUSION OF ACETAMINOPHEN IN CARDIAC SURGERY PATIENTS, Basic and Clinical Pharmacology and Toxicology 105: 26-27.
- Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt H, Danhof M, de Fijter H & Guchelaar H (2009), OPTIMIZING CALCINEURIN INHIBITOR EXPOSURE IN KIDNEY TRANSPLANT RECIPIENTS EARLY AFTER TRANSPLANTATION, Clinical Pharmacology and Therapeutics 85: S38S38.
- Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JCME, Verpoorte R, Pinquier JL, Cohen AF & van Gerven JMA (2008), Effect of intrapulmonary tetrahydrocannabinol administration in humans, Journal of Psychopharmacology 22(7).
- Willemze AJ, Cremers SC, Schoemaker RC, Lankester AC, den Hartigh J, Burggraaf J & Vossen JM (2008), Ciclosporin kinetics in children after stem cell transplantation, British Journal of Clinical Pharmacology 66(4).
- Zwaveling J, Press RR, Bredius RGM, van der Straaten TRJHM, den Hartigh J, Bartelink IH, Boelens JJ & Guchelaar HJ (2008), Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients, Therapeutic Drug Monitoring 30(4).
- Langers P, Press RR, den Hartigh J, Cremers SCLM, Baranski AG, Lamers CBHW, Hommes DW & van Hoek B (2008), Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration, Therapeutic Drug Monitoring 30(4).
- Langers P, Cremers SCLM, Press RR, den Hartigh J, Baranski A, Hommes DW & van Hoek B (2008), Development of a flexible accurate limited sampling model for monitoring tacrolimus after orthotopic liver transplantation: toward C4-monitoring, European Journal of Gastroenterology and Hepatology 20(7).
- Langers P, Press RR, Cremers S, den Hartigh J, Baranski AG, Hommes DW & van Hoek B (2008), ADVANCED MYCOPHENOLATE MOFETIL MONITORING STATEGY IN LIVER TRANSPLANTATION IN THE PRESENCE OR ABSENCE OF CALCINEURIN INHIBITORS, Hepatology 48(4).
- Bartelink IH, Bredius RGM, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CMA, den Hartigh J, Uiterwaal CSPM, Zwaveling J & Boelens JJ (2008), Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation, Biology of Blood and Marrow Transplantation 14(1).
- Zandvliet ML, Falkenburg JHF, Kester MGD, de Ru AH, van Veelen PA, Willemze R, Guchelaar HJ & Meij P (2008), Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation, Blood 112(11): 1330-1331.
- Zandvliet ML, Falkenburg JHF, Jedema I, Willemze R, Guchelaar HJ & Meij P (2008), Universal CD137 Expression upon Activation Allows Efficient Isolation of a Broad Repertoire of Virus-Specific CD8+and CD4+T Cells for Adoptive Immunotherapy, Blood 112(11): 774-775.
- Zandvliet ML, Falkenburg JHF, Veltrop-Duits LA, Schilham MW, Willemze R, Guchelaar HJ & Meij P (2008), Generation of Combined CD8+and CD4+T Cell Lines with High Specificity for Adenovirus Hexon Epitopes for Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation, Blood 112(11): 775-776.
- Press RR, Ploeger BA, den Hartigh J, van der Straaten RJHM, van Pelt J, Danhof M, de Fijter JW & Guchelaar HJ (2007), Dose prediction of tacrolimus in de novo kidney transplant patients with population pharmacokinetic modelling including genetic polymorphisms, Therapeutic Drug Monitoring 29(4).
- Press RR, Ploeger BA, den Hartigh J, Bemelman FJ, van der Heides JJH, Danhof M, Guchelaar HJ & de Fijter JW (2007), TDM of everolimus in stable renal transplant patients after CNI withdrawal, Therapeutic Drug Monitoring 29(4).
- Press RR, Ploeger BA, den Hartigh J, van der Straaten RJHM, van Pelt J, Danhof M, de Fijter JW & Guchelaar HJ (2007), Improved dose prediction of tacrolimusin de novo kidney transplant patients with population pharmacokinetic modelling including genetic polymorphismis., American Journal of Transplantation 7.
- Van der Vorst MMJ, Den Hartigh J, Wildschut E, Tibboel D & Burggraaf J (2007), An exploratory study with an adaptive continuous intravenous furosemide regimen in neonates treated with extracorporeal membrane oxygenation, Critical Care 11(5).
- Langers P, Cremers SCLM, den Hartigh J, Rijnbeek EMT, Ringers J, Lamers CBHW, Hommes DW & van Hoek B (2007), Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice, Alimentary Pharmacology and Therapeutics 26(10).
- Meij P, Zandvliet ML, van der Heiden PLJ, Jedema I, Egmond EM, Cox LMP, de Meent MV, Bongaerts R, Hoogstraten C, Guchelaar HJ, Willemze R & Falkenburg JHF (2007), Generation and administration of CMV pp65-specific donor T-cell lines for treatment of CMV reactivation after allogeneic stem cell transplantation, Bone Marrow Transplantation 39.
- De Fijter JW, Mourer JS, Den Hartigh J, Mallat MJ & Berger SP (2007), Concentration-controlled systemic exposure provides improved safety after CNI or MMF withdrawal., American Journal of Transplantation 7.
- van der Vorst MMJ, Holthe JEKV, den Hartigh J, van der Heijden AJ, Cohen AF & Burggraaf J (2007), Absence of tolerance and toxicity to high-dose continuous intravenous furosemide in haemodynamically unstable infants after cardiac surgery, British Journal of Clinical Pharmacology 64(6).
- Zandvliet ML, Falkenburg JHF, Jedema I, Willemze R, Guchelaar HJ & Meij P (2006), Generation of GMP-grade CMV pp65-specific CD8+and CD4+donor T cell lines for treatment of CMV reactivation after transplantation., Blood 108(11): 830A830A.
- Cremers S, Hollander J, Schrander-van der Meer A, Bet P, den Hartigh J, Vervloet M & Papapoulos S (2006), Removal of intravenous pamidronate by hemodialysis during infusion., Journal of Bone and Mineral Research 21.
- Zwaveling J, den Hartigh J, Lankester AC, Guchelaar HJ, Egeler RM & Bredius RGM (2006), Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomeos, Anti-Cancer Drugs 17(9).
- Scholten EM, Cremers SCLM, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC & de Fijter JW (2005), AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients, Kidney International 67(6).
- Cremers S, Schoemaker R, Scholten E, den Hartigh J, Konig-Quartel J, van Kan E, Paul L & de Fijter J (2005), Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling, British Journal of Clinical Pharmacology 60(3).
- Cremers SCLM, van Hogezand R, Banffer D, Hartigh J, Vermeij P, Papapoulos SE & Hamdy NAT (2005), Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease, Osteoporosis International 16(12).
- Cremers SCLM, Papapoulos SE, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P, van der Rijt CCD & van Zuylen L (2005), Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases, Journal of Bone and Mineral Research 20(9).
- Langers P, Cremers SCLM, Hartigh J, Rijnbeek EMT, Ringers J, Lamers CBHW & Van Hoek B (2005), Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation, Alimentary Pharmacology and Therapeutics 21(5).
- Zwaveling J, Bredius RGM, Cremers SCLM, Ball LM, Lankester AC, Teepe-Twiss IM, Egeler RM, den Hartigh J & Vossen JM (2005), Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity, Bone Marrow Transplantation 35(1).
- Cremers S, Banffer D, den Hartigh J, Vermeij P & van Hogezand R (2004), Renal excretion of alendronate in relation to bone turnover in patients with Crohn's disease, BONE 34.
- Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PEM & Dahan A (2004), Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers - Absence of sex differences, Anesthesiology 100(1).
- Cremers SCLM, Lodder MC, Den Hartigh J, Vermeij P, Van Pelt PA, Lems WF, Papapoulos SE & Dijkmans BAC (2004), Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis, Journal of Rheumatology 31(9).
- Langers P, Cremers SCLM, den Hartigh J, Veenendaal RA, ten Hove WR, Ringers J, Lamers CBHW & van Hoek B (2004), Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients, Liver Transplantation 10(2).
- Cremers S, Lodder M, den Hartigh J, Vermeij P, van Pelt P & Lems W (2004), Short-term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis, BONE 34.
- Cremers S, van Zuylen L, Gelderblom H, Seynaeve C, den Hartigh J, Pols H, Vermeij P, van der Rijt C & Papapoulos S (2004), Pharmacokinetics and pharmacodynamics of intravenous pamidronate in patients with breast cancer and bone metastases, BONE 34.
- Cremers SCLM, Scholten EM, Schoemaker RC, Lentjes EGWM, Vermeij P, Paul LC, den Hartigh J & de Fijter JW (2003), A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients, Nephrology Dialysis Transplantation 18(6).
- Cremers SCLM, Eekhoff MEMW, Den Hartigh J, Hamdy NAT, Vermeij P & Papapoulos SE (2003), Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone, Journal of Bone and Mineral Research 18(5).
- Cremers SCL, Papapoulos SEP, Gelderblom H, Seynave C, den Hartigh J, Pols H, Vermeij R, van der Rijt C & van Zuylen L (2003), Pharmacokinetics and pharmacodynamics (PK/PD) of intravenous pamidronate in patients with breast cancer and bone metastases., Journal of Bone and Mineral Research 18.
- Cremers S, Schoemaker R, Bredius R, den Hartigh J, Ball L, Twiss I, Vermeij P & Vossen J (2002), Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation, British Journal of Clinical Pharmacology 53(4).
- Cremers S, Sparidans R, den Hartigh J, Hamdy N, Vermeij P & Papapoulos S (2002), A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis, European Journal of Clinical Pharmacology 57(12).
- Cremers S, Eekhoff E, van Dam S, Den Hartigh J, Hamdy H, Vermeij P & Papapoulos S (2002), Bisphosphonate (olpadronate) retention and its determinants in Paget's disease of bone, British Journal of Clinical Pharmacology 53(5).
- Twiss IM, Burggraaf J, Schoemaker RC, van Elburg RM, den Hartigh J, Cohen AF & Vermeij P (2001), The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: Studies with oral pamidronate, Clinical Pharmacology and Therapeutics 69(6).
- Schippers EF, Hugen PWH, den Hartigh J, Burger DM, Hoetelmans RMW, Visser LG & Kroon FP (2000), No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients, AIDS 14(17).
- Sparidans RW, den Hartigh J, Cremers S, Beijnen JH & Vermeij P (2000), Semi-automatic liquid chromatographic analysis of olpadronate in urine and serum using derivatization with (9-fluorenylmethyl)chloroformate.
- Franken KLMC, Hiemstra HS, van Meijgaarden KE, Subronto Y, den Hartigh J, Ottenhoff THM & Drijfhout JW (2000), Purification of His-tagged proteins by immobilized chelate affinity chromatography: The benefits from the use of organic solvent.
- Sparidans RW, den Hartigh J, Cremers S & Vermeij P (2000), Chromatographic analysis of bisphosphonates.
- Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, Nieuwenhuijs D, Burm A, Teppema L & Dahan A (2000), Sex differences in morphine analgesia - An experimental study in healthy volunteers, Anesthesiology 93(5).